FDA nanotechnology draft guidance represents ‘marginal progress’ – petition group
date:May 10, 2012
er ignoring the scientific consensus that these nanomaterials have the capacity to be fundamentally different, and can create new and novel risks, necessitating new testing, said Kimbrell.


Unfortunately, the agency has thus far only taken a voluntary rather than mandatory regulatory approach, despite the failure of voluntary approaches to elicit industry cooperation to regulate nanomaterials.


Much more than voluntary guidance is needed, and we will remain vigilant in our efforts to drag the
6/7 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
12/29 03:49